About this policy
CMS evidence review | evidence_type=MEDCAC Meeting | record_type=medcac_meeting | document_id=14 | meeting_date=1999-11-15
Coverage indications
Human Tumor Assay Systems are tests that detect resistance and/or sensitivity to chemotherapeutic agents. The Coverage Issues Appendix, §50-41 now reads: "Human tumor drug sensitivity assays are considered experimental, and therefore, not covered under Medicare at this time." HCFA must evaluate whether current literature supports the accuracy of available chemosensitivity testing; and, whether the assays are "reasonable and necessary" oncology treatment.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.